NCT05354765 Exploration of Adaptive Antitumoral Immune Cells Through Lymphapheresis in Cancer Patients : ALCYTA
| NCT ID | NCT05354765 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Curie |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2022-08-31 |
| Primary Completion | 2027-09-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2022-08-31 with a primary completion date of 2027-09-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study will evaluate the detection of tumor-antigen specific immune cells in cancer patients in whom the role of the immune system is suspected.
Eligibility Criteria
Inclusion Criteria: 1. Patient aged 18 or over, 2. Patient presenting an invasive tumor pathology (proven or suspected). The location and / or stage of which are defined for each cohort through an amendment to the protocol, 3. Patient treated with immune-modulators or other treatments likely to modify immunological parameters, 4. Suspicion of immune mediated response or toxicities (assessed by the immunologists), 5. Peripheral venous capital usable and compatible with the realization of 2 venous accesses for lymphapheresis and absence of cardiovascular problem (heart failure, arrhythmia ...), per investigator assessement, 6. Total circulating lymphocytes\> 1000 / mm3, 7. Availability of DNA and RNA from the tumor, 8. Information to the patient and signature of informed consent or his legal representative, 9. Affiliated with a social security scheme or such a scheme. Exclusion Criteria: 1. Inability to undergo study follow-up for geographical, social or psychological reasons, 2. Infection with HIV or hepatitis B or C viruses, 3. Patients on high dose corticosteroid treatment (\> 1 mg / kg continuously), 4. Any concomitant serious illness that may interfere with participation in the study or significantly affect the results of the study (pulmonary, heart or liver disease), 5. Contraindication to performing lymphapheresis (coagulation disorder, cardiovascular problems, venous access, hypocalcemia, psychological inability to undergo extracorporeal circulation, cachexia, etc.), 6. Pregnant patient or of childbearing age without effective contraception, 7. Persons deprived of their liberty, under guardianship or legal protection.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05354765 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05354765 currently recruiting?
Yes, NCT05354765 is actively recruiting participants. Contact the research team at cyrine.ezzili@curie.fr for enrollment information.
Where is the NCT05354765 trial being conducted?
This trial is being conducted at Paris, France, Saint-Cloud, France.
Who is sponsoring the NCT05354765 clinical trial?
NCT05354765 is sponsored by Institut Curie. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.